Latest advancements in TB science in spotlight

    26-May-2022
|
Bobby Ramakant – CNS
Contd from previous issue
PHOENix (Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients) study is comparing Delamanid with Isoniazid for preventing MDR-TB in children, adolescents and adults who are close contacts of persons with MDR-TB.
V-QUIN study in Vietnam is examining the efficacy of Levofloxacin for treating latent MDR-TB in all household contacts of patients with bacteriologically-confirmed Rifampicin-resistant TB.
Research ongoing for long-acting injectables for treating TB
Long-acting injectable possible formulations of TB drugs could have several potential benefits, like improved adherence, greater acceptability, and better integration of TB preventive therapy into other treatment programmes, like those for HIV, maternal and child health, said Shobha Shukla.
CROI also shared information on new TB drugs, including long acting injectables, that are in various stages of development: TBAJ-876, a next generation diarylquinoline, is in phase-1 of multiple ascending dose (MAD) study. (To be contd)